Emmaus Life Sciences, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Endari US at $9.0 million, 73% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Sep 30, 2018
|
FY 2017
Sep 30, 2017
|
FY 2016
Sep 30, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16
|
12
|
17
|
30
|
18
|
21
|
23
|
23
|
1
|
—
|
—
|
| Endari |
—
|
—
|
—
|
—
|
18
-11.2%
share 97.1%
|
20
-10.8%
share 97.6%
|
23
share 97.4%
|
—
|
—
|
—
|
—
|
| Endari US |
12
share 77.6%
|
9
-32.9%
share 72.7%
|
13
-38.7%
share 80.9%
|
22
share 74.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Endari International |
3
share 21.8%
|
3
+19.1%
share 25.5%
|
3
-61.7%
share 16.0%
|
7
share 23.5%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Product And Service Other |
0
-80.2%
share 0.6%
|
0
-55.5%
share 1.8%
|
1
-20.4%
share 3.0%
|
1
+18.7%
share 2.1%
|
1
+8.7%
share 2.9%
|
0
-18.2%
share 2.4%
|
1
share 2.6%
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EMMA (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Torrance, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 822370
- Former names
- MYnd Analytics, Inc. (until Jul 12, 2019); CNS RESPONSE, INC. (until Dec 10, 2015); STRATIVATION, INC. (until Mar 1, 2007); SalesTactix, Inc. (until Aug 23, 2005); AGE RESEARCH INC (until Aug 5, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.